Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

British Journal of Cancer：miR-126或为口腔鳞癌诊治靶标

2012-07-31 魏冬 医学论坛网

miR-126口腔鳞状细胞癌
关注

　　 　　《英国癌症杂志》（British Journal of Cancer）近期发表的一项研究表明，微RNA-126（miR-126）可能是口腔鳞状细胞癌（OSCC）诊断和治疗的一个有用靶标。 　　miR-126是一个内皮特异性miRNA，位于表皮生长因子样结构域7（EGFL7）的内含子7。但是，miR-126在癌症中的作用尚存争议。 　　研究者评估了miR

　　口腔鳞癌

　　《英国癌症杂志》（British Journal of Cancer）近期发表的一项研究表明，微RNA-126（miR-126）可能是口腔鳞状细胞癌（OSCC）诊断和治疗的一个有用靶标。

　　miR-126是一个内皮特异性miRNA，位于表皮生长因子样结构域7（EGFL7）的内含子7。但是，miR-126在癌症中的作用尚存争议。

　　研究者评估了miR-126在OSCC细胞中的功能，并评估了118例OSCC患者的miR-126表达水平。

　　结果显示，miR-126与细胞生长及血管内皮生长因子A活性调控相关。去甲基化处理提高OSCC细胞miR-126和EGFL7表达水平。

　　miR-126表达与肿瘤进展、淋巴结转移、血管敏度和预后较差呈显著相关性。

　　多变量分析显示，miR-126表达下调与无病生存呈强相关性。

　　相关链接：

T Sasahira, M Kurihara, U K Bhawal, N Ueda, T Shimomoto, K Yamamoto, T Kirita and H Kuniyasu,Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer.British Journal of Cancer ,26 July 2012



    

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=6032, encodeId=e00e6032c9, content=好可怕啊，的好好治, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=14.134.18.233, createdTime=Thu Aug 08 09:47:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935511, encodeId=94ed1935511aa, content=<a href='/topic/show?id=7b88118167e' target=_blank style='color:#2F92EE;'>#miR-126#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11816, encryptionId=7b88118167e, topicName=miR-126)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sun Jan 13 02:50:00 CST 2013, time=2013-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930360, encodeId=90c0193036099, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Sep 11 12:50:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352704, encodeId=062f1352e0403, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 02 01:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484592, encodeId=ee2914845920b, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Thu Aug 02 01:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
    2013-08-08 14.134.18.233

    好可怕啊，的好好治

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=6032, encodeId=e00e6032c9, content=好可怕啊，的好好治, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=14.134.18.233, createdTime=Thu Aug 08 09:47:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935511, encodeId=94ed1935511aa, content=<a href='/topic/show?id=7b88118167e' target=_blank style='color:#2F92EE;'>#miR-126#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11816, encryptionId=7b88118167e, topicName=miR-126)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sun Jan 13 02:50:00 CST 2013, time=2013-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930360, encodeId=90c0193036099, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Sep 11 12:50:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352704, encodeId=062f1352e0403, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 02 01:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484592, encodeId=ee2914845920b, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Thu Aug 02 01:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
    2013-01-13 1249857fm32暂无昵称

    #miR-126#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=6032, encodeId=e00e6032c9, content=好可怕啊，的好好治, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=14.134.18.233, createdTime=Thu Aug 08 09:47:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935511, encodeId=94ed1935511aa, content=<a href='/topic/show?id=7b88118167e' target=_blank style='color:#2F92EE;'>#miR-126#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11816, encryptionId=7b88118167e, topicName=miR-126)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sun Jan 13 02:50:00 CST 2013, time=2013-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930360, encodeId=90c0193036099, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Sep 11 12:50:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352704, encodeId=062f1352e0403, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 02 01:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484592, encodeId=ee2914845920b, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Thu Aug 02 01:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
    2012-09-11 smallant2002

    #miR#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=6032, encodeId=e00e6032c9, content=好可怕啊，的好好治, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=14.134.18.233, createdTime=Thu Aug 08 09:47:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935511, encodeId=94ed1935511aa, content=<a href='/topic/show?id=7b88118167e' target=_blank style='color:#2F92EE;'>#miR-126#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11816, encryptionId=7b88118167e, topicName=miR-126)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sun Jan 13 02:50:00 CST 2013, time=2013-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930360, encodeId=90c0193036099, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Sep 11 12:50:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352704, encodeId=062f1352e0403, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 02 01:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484592, encodeId=ee2914845920b, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Thu Aug 02 01:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
    2012-08-02 zhaojie88

    #靶标#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=6032, encodeId=e00e6032c9, content=好可怕啊，的好好治, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=14.134.18.233, createdTime=Thu Aug 08 09:47:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935511, encodeId=94ed1935511aa, content=<a href='/topic/show?id=7b88118167e' target=_blank style='color:#2F92EE;'>#miR-126#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11816, encryptionId=7b88118167e, topicName=miR-126)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Sun Jan 13 02:50:00 CST 2013, time=2013-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930360, encodeId=90c0193036099, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Sep 11 12:50:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352704, encodeId=062f1352e0403, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 02 01:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484592, encodeId=ee2914845920b, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Thu Aug 02 01:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
    2012-08-02 1696533704_45270456

    #鳞癌#

    0

Baidu
map
Baidu
map
Baidu
map